ALISO VIEJO, Calif., April 28 /PRNewswire/ -- Ambry Genetics announced today that it has successfully completed Illumina CSPro(TM) certification for Genome Analyzer (GA) Sequencing, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.
Anja Kammesheidt, PhD, Ambry's CSO, said, "that the company has been working on the Illumina GA systems since January 2008. We are offering standard GA Sequencing services to pharma, clinical and academic research groups, while keeping up with Illumina's technology improvements. We value Illumina's commitment to innovation and quality, and are excited to now be the second CSPro in the USA for the GA applications."
"Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Director of Corporate Marketing. "Ambry Genetics is the now a Certified Service Provider able to offer Illumina Genome Analyzer Sequencing services using Illumina technology. Now that Ambry Genetics is a global CSPro partner, we are excited to work with them to make it easier for researchers to access the power of Illumina's genetic analysis technologies."
About Ambry Genetics
Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics, pharmacogenomics and research support. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies. To learn more about testing and services available through Ambry, visit www.ambrygen.com.
This report contains forward-looking statements about the Company's future plans, strategies, objectives, goals and expectations, including projections, estimates, prospects, returns and performance of the Company. Forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereof or comparable terminology. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements made in this report the inclusion of such information should not be regarded as a representation or warranty, express or implied, by the Company or any other person that the objectives and plans of the Company will be achieved.
|SOURCE Ambry Genetics|
Copyright©2009 PR Newswire.
All rights reserved